ArticleWorld journal of surgical oncology2025
Assessment of carbon nanoparticle suspension in sentinel lymph nodes biopsy for acral melanoma.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAcral melanoma is characterized by high propensity of lymph node metastasis. Accurate diagnosis and staging are important for patient management.
objectiveThis study aimed to evaluate the efficacy of carbon nanoparticle suspension (CNS) as a tracer in SLNB for AM and to compare its performance with methylene blue (MB) and 99mTc. And it aimed To improve the technology of accurate diagnosis and treatment in melanoma. METHODS & MATERIALS: A retrospective analysis was conducted on 71 patients who underwent surgery between January 2022 and August 2024 at our hospital. Patients were divided into CNS group (Group 1 ; n = 46), and methylene blue group (Group 2 ; n = 25). In Group 1, 10 patients of all patients underwent 99mTc-single-photon emission computed tomography (SPECT) to assess lymphatic drainage. The sentinel lymph node (SLN) detection rate, lymph node metastasis rate, and number of lymph nodes detected were compared between the two groups. Two-tailed t-testsm Chi-square tests and Fisher tests were used in this study.
resultsGroup 1 achieved a significantly higher SLN detection rate (100% vs. 84%, P = 0.013) and identified more nodes on average. No significant difference was observed in the detection rate of patients with metastasis between the groups(30.4% vs. 24%, P = 0.565). The CNS tracer showed highly concordance with the SPECT findings in subgroup of Group 1, indicating its effective lymph node tracing.
conclusionCNS is an effective tracer in SLNB, surpassing methylene blue in efficacy. It significantly improved the detection rate of sentinel lymph nodes. Its use enhances surgical precision and offers a valuable method for the accurate staging and management of acral melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.